

Result No.	Query *			DB ID	Description
	Score	Match	Length		
1	1192	100.0	227	21	A human monocyte-d
2	1192	100.0	291	19	Human secreted pro
3	1192	100.0	326	22	Human secreted pro
4	1179	98.9	227	21	Human signal pepti
5	1163.5	97.6	226	20	Human LSP-1 protei
6	1163.5	97.6	226	21	A human monocyte-d
7	1157.5	97.1	226	19	A secreted protein
8	1157.5	97.1	226	23	Human polypeptide
9	958	80.4	303	19	Human immunoglob
10	958	80.4	303	21	A human monocyte-d

RESULT 1	
AAB07445	
ID AAB07445 standard; Protein; 227 AA.	
XX	
AC AC	AAB07445;
DT DT	20-OCT-2000 (first entry)
XX XX	A human monocyte-derived protein FDF03-S1.
DE DE	Human; monocyte-derived protein; FDF03; PD
XX XX	FDF03-M14; FDF03-S2; haematopoietic cell;
KW KW	tissue rejection; inflammation; infection;
KW KW	
XX XX	OS Homo sapiens.
XX XX	Key Location/Qualifiers
FF FF	1..17
FT FT	/note= "signal sequence"
FT FT	18..227
FT FT	/note= "mature protein"
XX XX	
PN PN	WO200040721-A1.
XX XX	13-JUL-2000.
XX XX	
PB PB	29-DEC-1999; 99WO-US30004.
XX XX	
PP PP	31-DEC-1998; 98US-0223919.
PR PR	31-DEC-1998; 98US-0224604.
XX XX	(SCHE ) SCHERING CORP.
PA PA	
XX XX	

PI Bates E, Fournier N, Chaulus L, Garrone P;  
 DR WPI; 2000-465984/40.  
 DR N-PSDB; AAW5816.  
 XX  
 PT Novel monocytic-derived polypeptides and polynucleotides, used to  
 PT diagnose diseases associated with changes in monocyte numbers, e.g.  
 PT bacterial or viral infections -  
 XX  
 PS Claim 1; Page 37-38; 45pp; English.  
 XX  
 CC The present sequence represents a human monocyte-derived protein. The  
 CC specification describes monocyte-derived proteins PFO3, PFO3DeltaTM,  
 CC PFO3-S1, PFO3-M14, and PFO3-S2. The proteins are involved in the  
 CC regulation, or development, of haematopoietic cells. Antibodies specific  
 CC for antigenic components of the proteins can be used to detect the  
 CC components in samples. The proteins can also be used to screen for  
 CC candidate therapeutic agents. The monocyte-derived proteins and  
 CC polynucleotides can be used for diagnosis of diseases related to an  
 CC increase, or decrease, in the number of monocytes in a tissue or  
 CC lymph system, such as monocyte hyperplasia, tissue or graft rejection,  
 CC inflammation, or bacterial or viral infections. The proteins can also  
 CC be used in the treatment of disorders associated with abnormal expression  
 CC or signalling by a monocyte.  
 XX  
 SQ Sequence 227 AA;  
 CC  
 CC Query Match 100.0%; Score 1192; DB 21; Length 227;  
 CC Best Local Similarity 100.0%; Pred. No. 5.1e-99;  
 CC Matches 227; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 CC  
 CC QY 1 MGRPLLLPLLLLOPPAFLOPGSGTSGPSYLYGVTPQKHLASMGSGVEIPFSFYFPE 60  
 CC Db 1 MGRPLLLPLLLLOPPAFLOPGSGTSGPSYLYGVTPQKHLASMGSGVEIPFSFYFPE 60  
 CC  
 CC QY 61 LAIVPNVRISWRGPHGSGFYSTRPSTHKDYVNLFLNWTGEGSGFLRISNLRKEDQ 120  
 CC Db 61 LAIVPNVRISWRGPHGSGFYSTRPSTHKDYVNLFLNWTGEGSGFLRISNLRKEDQ 120  
 CC  
 CC QY 121 SVYFCRVELDTRRSGRQQLQSIKGTKLITQAVTTTTWRPSTTTIAGLRVTSKGHSE 180  
 CC Db 121 SVYFCRVELDTRRSGRQQLQSIKGTKLITQAVTTTTWRPSTTTIAGLRVTSKGHSE 180  
 CC  
 CC QY 181 SWHLSLDTAIRVALAVAVLTKVILGLLCLLLWRRRKGSRAPSSDF 227  
 CC Db 181 SWHLSLDTAIRVALAVAVLTKVILGLLCLLLWRRRKGSRAPSSDF 227  
 CC  
 CC RESULT 2  
 CC AAW63682  
 CC ID AAW63682 standard; Protein; 291 AA.  
 CC AC AAW63682;  
 CC XX  
 CC DT 24-SEP-1998 (first entry)  
 CC DE Human secreted protein 2.  
 CC XX  
 CC KW Secreted protein; human; cell proliferation; cytokine activity;  
 CC KW tissue growth; cellular differentiation; regeneration; activin;  
 CC KW inhibin; chemotactic; haemostatic; thrombolytic; tumour inhibition;  
 CC KW anti-inflammatory activity; biomarker.  
 CC XX  
 CC OS Homo sapiens.  
 CC XX  
 CC PN W09825959-A2.  
 CC XX  
 CC PD 18-JUN-1998.  
 CC XX  
 CC PF 11-DEC-1997; 97WO-US22787.  
 CC XX  
 CC PR 11-DEC-1996; 96US-0032757.  
 CC XX

PA (CHIR) CHIRON CORP.  
 XX Escobedo J, Garcia P, Hu Q, Kothakota S, Williams LT;  
 PI WPI; 1998-348453/30.  
 XX N-PSDB; AAV43602.  
 DR  
 DR Secreted human polypeptides - having cytokine, cell proliferation or  
 PT differentiation, activin or inhibin, tumour inhibition or  
 PT anti-inflammatory activities  
 XX  
 XX Claim 1; Pages 49-50; 78pp; English.  
 PS  
 XX This represents a human secreted protein. The specification provides  
 CC secreted protein sequences (AAW63681 to AAW63699) encoded by the nucleic  
 CC acid sequences shown in AAV43601 to AAV43619. The invention provides a  
 CC method of identifying a secreted polypeptide which is modified by rough  
 CC microsomes. The secreted proteins can be used in assays to determine  
 CC biological activities, such as cytokine, cell proliferation, or cellular  
 CC differentiation activities, tissue growth or regeneration, activin or  
 CC inhibin activity, chemotactic or chemokinetic activity, haemostatic or  
 CC thrombolytic activity, receptor/ligand activity, tumour inhibition, or  
 CC anti-inflammatory activity. The proteins can also be used as  
 CC biomarkers, to identify tissues or cell types which express the proteins,  
 CC or a stage- or disease-specific alteration in protein expression. They  
 CC can be used in protein interaction assays, to identify ligands or binding  
 CC proteins. Compounds which affect the biological activities of the  
 CC secreted proteins or their ability to interact with specific ligands can  
 CC be identified using the proteins in screening assays. The proteins and  
 CC antibodies that bind specifically to the protein can also be used to  
 CC design diagnostic tests and therapeutic compositions for diseases which  
 CC may be associated with altered expression of these proteins. Fusion  
 CC proteins comprising, e.g. signal sequences or transmembrane domains of  
 CC the proteins can be used to target other protein domains to cellular  
 CC membrane or they can be secreted extracellularly.  
 CC  
 CC SQ Sequence 291 AA;  
 CC  
 CC Query Match 100.0%; Score 1192; DB 19; Length 291;  
 CC Best Local Similarity 100.0%; Pred. No. 6.9e-99;  
 CC Matches 227; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 CC  
 CC QY 1 MGRPLLLPLLLLOPPAFLOPGSGTSGPSYLYGVTPQKHLASMGSGVEIPFSFYFPE 60  
 CC Db 65 MGRPLLLPLLLLOPPAFLOPGSGTSGPSYLYGVTPQKHLASMGSGVEIPFSFYFPE 124  
 CC  
 CC QY 61 LAIVPNVRISWRGPHGSGFYSTRPSTHKDYVNLFLNWTGEGSGFLRISNLRKEDQ 120  
 CC Db 125 LAIVPNVRISWRGPHGSGFYSTRPSTHKDYVNLFLNWTGEGSGFLRISNLRKEDQ 184  
 CC  
 CC QY 121 SVYFCRVELDTRRSGRQQLQSIKGTKLITQAVTTTTWRPSTTTIAGLRVTSKGHSE 180  
 CC Db 185 SVYFCRVELDTRRSGRQQLQSIKGTKLITQAVTTTTWRPSTTTIAGLRVTSKGHSE 244  
 CC  
 CC QY 181 SWHLSLDTAIRVALAVAVLTKVILGLLCLLLWRRRKGSRAPSSDF 227  
 CC Db 245 SWHLSLDTAIRVALAVAVLTKVILGLLCLLLWRRRKGSRAPSSDF 291  
 CC  
 CC RESULT 3  
 CC ABB12010  
 CC ID ABB12010 standard; peptide; 326 AA.  
 CC XX  
 CC AC ABB12010;  
 CC XX  
 CC DT 11-JAN-2002 (first entry)  
 CC DE Human secreted protein homologue, SEQ ID NO:2380.  
 CC XX  
 CC KW Human; cytokine; cell proliferation; cell differentiation; growth factor;  
 CC KW haematopoiesis regulation; tissue growth; immunomodulator; activin;  
 CC KW inhibin; chemotaxis; chemokinesis; thrombolysis; oncogenesis;  
 CC KW proliferation; metastasis; cancer; tumour; haematopoietic disorder;